Related Experiment Videos
[Development and current status of Pseudomonas aeruginosa sensitivity to antibiotics]
Abstract:
The response of Pseudomonas aeruginosa to antibacterial drugs is remarkably stable and is characterized by multiresistance. This organism is uniformly resistant to ampicillins, first and second generation cephalosporins and kanamycin and most often resistant to streptomycin, tetracyclines, chloramphenicol, nalidixic acid, sulphonamides, co-trimoxazole and nitrofurans. Very few of the conventional antibiotics are active against Pseudomonas spp.: polymyxin is virtually always active in vitro but gives disappointing therapeutic results; little change has been observed over years in the incidence of strains resistant to carbenicillin and to some aminoglycosides, such as gentamicin, tobramycin and amikacin. Recently developed antibacterial agents of the beta-lactam and quinolone groups offer hopes of better therapeutic effectiveness. Among beta-lactam antibiotics, new penicillins, including azlocillin, are more active than carbenicillin and some third generation cephalosporins, notably cefoperazone, cefsulodin and ceftazidime, also show anti-Pseudomonas activity. The same applies to new beta-lactam antibiotics with a novel structure, such as thienamycins and monobactams. Several new quinolones are active in vitro against Ps. aeruginosa; these are rosoxacin, norfloxacin, enoxacin, pefloxacin, ciprofloxacin and ofloxacin.
Insights
Pseudomonas aeruginosa exhibits stable multidrug resistance to many common antibiotics. Newer beta-lactam and quinolone antibiotics show promise for treating infections caused by this resilient bacterium.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Pseudomonas aeruginosa demonstrates significant and stable multidrug resistance to numerous conventional antibacterial agents.
- Many antibiotics, including ampicillins, cephalosporins, and certain aminoglycosides, are ineffective against this opportunistic pathogen.
- Polymyxin remains active in vitro but yields poor therapeutic outcomes, highlighting the need for alternative treatments.
Purpose of the Study:
- To review the resistance patterns of Pseudomonas aeruginosa to various antibacterial drugs.
- To evaluate the in vitro activity of established and novel antibacterial agents against Pseudomonas aeruginosa.
- To identify promising therapeutic options for Pseudomonas aeruginosa infections.
Main Methods:
- Literature review of antibiotic resistance profiles in Pseudomonas aeruginosa.
- Analysis of in vitro susceptibility data for conventional and new-generation antibiotics.
- Comparison of the efficacy of different antibiotic classes, including beta-lactams and quinolones.
Main Results:
- Pseudomonas aeruginosa is uniformly resistant to ampicillins, early-generation cephalosporins, and kanamycin.
- Resistance is common to streptomycin, tetracyclines, chloramphenicol, and other agents.
- Newer beta-lactams (e.g., azlocillin, third-generation cephalosporins) and novel beta-lactams (thienamycins, monobactams) show enhanced anti-Pseudomonas activity.
- Several new quinolones, including ciprofloxacin and ofloxacin, exhibit in vitro activity.
Conclusions:
- The stable multidrug resistance of Pseudomonas aeruginosa necessitates the development of effective therapeutic strategies.
- Novel beta-lactam and quinolone antibiotics represent promising alternatives for treating Pseudomonas aeruginosa infections.
- Continued research into new antibacterial agents is crucial to combat resistant strains.